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1. INTRODUCTION 
A medicine is a substance or combination of substances intended to prevent, 
diagnose or cure  a disease or its symptoms, to relieve a disease condition in a 
human or animal, or to restore or alter vital functions in a human or animal 
through pharmacological, immunological or metabolic effect (1). However, a 
medicine is only effective if the patient takes it and in terms of a chronic 
condition, does so for a sufficient period of time (2). 
The concept of patients taking medicines as prescribed by their healthcare 
provider is termed medication adherence (3). Compliance or concordance are 
sometimes used to describe the same concept, but recently it has been agreed 
that medication adherence is the preferred term. This is mainly because 
compliance implies the patient must obey their doctor’s order, but in reality the 
medication process requires cooperation between the prescriber and patient. 
Concordance is actually a different concept that refers to the discussion between 
physician and patient during which agreement is reached regarding a suitable 
treatment plan (4). 
Medication adherence can be divided into primary and secondary adherence. 
Primary adherence describes whether the patient purchases the medicines from 
the pharmacy after the initial prescription and starts the treatment in the first 
place. Secondary adherence follows the behaviour of the patient after the first 
dispensing from the pharmacy until the discontinuation of treatment (5). 
Secondary adherence can in turn be divided into three different concepts: the 
initiation of treatment, implementation of the dosing regimen and discon-
tinuation of therapy, while persistence is the length of time between initiation 
and discontinuation of therapy (4). 
Medication non-adherence is the most important reason why the efficacy 
medicines show in clinical trials are not reached in real life clinical practice (6). 
It has been assessed that on average only 50% of patients sufficiently adhere to 
treatment plans (7). When a patient does not take the medicines as agreed upon 
with a physician, they do not meet the clinical endpoints aimed at, and often put 
additional pressure on healthcare services via the need to treat complications 
that were not prevented because of the patient’s poor adherence to the initial 
treatment (8). 
Osteoporosis is a chronic disease characterized by the loss of bone tissue and 
as a consequence bone fragility (9). If bones are fragile fractures may occur 
following a low force trauma. Osteoporosis is often asymptomatic until a 
fracture but after a fracture in a major site (e.g. the hip or spine) the quality of 
life of the patient is significantly reduced (10). There are effective treatment 
options available that decrease the risk of fractures but the asymptomatic nature 
of the disease makes adherence to these medicines is suboptimal (11). 
In Estonia the preconditions for quantitative and qualitative drug utilization 
research are very high. The State Agency of Medicines (SAM) collects package 
level consumption data from medicine wholesalers that covers 100% of drug 
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use in Estonia (ambulatory care and hospital care, prescription medicines and 
over-the-counter medicines). This data dates back to 1994 and enables long-
term quantitative research. The Estonian Health Insurance Fund (EHIF) collects 
patient level prescription and dispensing data and also data on healthcare 
services that are provided to a patient. All EHIF insured patients are included in 
this database, providing data on more than 95% of ambulatory prescription 
drugs in Estonia. Dispensing data is available from 2004 onwards and enables 
qualitative utilization research. In 2010 ePrescribing was implemented in Esto-
nia, which enabled primary adherence to be calculated by comparing pre-
scription data with dispensing data. Estonia’s ePrescription system is one of the 
most comprehensive in Europe, with only Denmark and Sweden reported to 
have a digital prescribing system that covers all prescriptions and pharmacies in 
the country (12). 
The aim of the current thesis was to use Estonian data to establish the 
general utilization of osteoporosis medicines in Estonia and explore the possible 
connection between trends in osteoporosis related fractures and the con-
sumption of medicines. Furthermore to ascertain primary and secondary adhe-
rence to osteoporosis medicines, including which patient characteristics influen-
ce adherence. 
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2. REVIEW OF LITERATURE 
2.1. Osteoporosis 
Osteoporosis (OP) is a major health problem (13) and cause of morbidity and 
mortality in the Western world (14,15). OP is a growing chronic health condi-
tion that is putting a significant load on both patients and society (16). OP alters 
bone quality and architecture, making bones more fragile and susceptible to 
fractures (9). The annual number of fractures in Europe is expected to increase 
around 30% during the period from 2010 to 2025, with a total cost related to OP 
induced fractures of approximately 120 billion EUR in 2025 (17). It has been 
demonstrated that the estimated number of fractures per a certain population is 
most sensitive to assumptions made using rate of fracture incidence trends (18), 
thus if the trend in fractures is reduced, the estimated numbers are not reached. 
One way to reduce the trend in OP induced fractures is effective pharma-
cotherapy (19). 
OP is characterized by reduced bone mineral density (BMD) and disruption 
of bone microarchitecture, resulting in increased bone fragility and increased 
fracture risk (9,20). Bone is a living tissue that is constantly being renewed. 
Two activities maintain bone homeostasis: bone formation by osteoblasts; and 
bone resorption by osteoclasts (21). Under pathologic conditions, this balance is 
disrupted. High osteoclast activity or low osteoblast activity leads to low bone 
mass (osteoporosis), while low osteoclast activity or high osteoblast activity 
leads to high bone mass (osteopetrosis) (22). Loss of bone mass per se and OP 
are usually asymptomatic until a fracture occurs (2). The disease has clinical 
and public health importance only because of the fractures (23), which cause 
pain, degrade people’s quality of life, and are often disabling (10). Clinically, 
osteoporosis is recognized by the occurrence of characteristic fractures after 
low-energy trauma; usually these are fractures of the hip, vertebrae, or distal 
forearm (24). 
Fracture incidence trends have been shown to differ in different parts of the 
world (25). This indicates a need for local research on possible changes in the 
incidence rate of OP induced fractures. The potential drivers of negative 
changes to fracture rates are urbanization and a general aging of the population. 
Conversely osteoporosis medication use, birth cohort effects such as maternal 
and offspring nutrition, an increase in BMI, and lifestyle interventions such as 
smoking cessation and fall prevention, can result in a more positive trend 
(26,27). Increasing the consumption of osteoporosis medicines per a population 
has been shown to be one of the main factors that could positively influence 
fracture incidence trends (28,29). However, it has also been acknowledged that 
these results need to be verified among local populations and countries (30). 
To alleviate the public and private burden of osteoporosis related fractures, 
risk assessments and a reduction in individuals’ risk of fractures are critical 
(31). Key steps highlighted to tackle osteoporosis are: awareness raising 
campaigns; preventive lifestyle strategies; evidence-based guidelines; fracture 
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care; post-fracture rehabilitation and prevention of falls; economic data and an 
European fracture database (32). However, the exact loss of quality adjusted life 
years (QALY) following a fracture is difficult to assess, as various research has 
reported different utility (33). 
Losing bone mass and quality is a normal part of the ageing process, but 
some people lose bone density at a higher than average rate and this can lead to 
the development of OP and fractures. Postmenopausal women are most affected 
by bone loss, due to changes in levels of reproductive hormones (34,35). 
Although men are less disposed to osteoporosis, they have been shown to be 
undertreated, thus also cannot go unrecognised when interventions to improve 
the quality of treatment are planned (36). There are many other diseases and 
factors that can increase bone loss and the risk of developing of OP, including: 
diabetes; several hormone-related conditions (hyperthyroidism, hyperparathy-
roidism, Cushing’s disease); rheumatoid arthritis; malabsorption problems; long 
term use of high dose glucocorticoids; insufficient calcium and vitamin D 
intake; low physical activity; increased alcohol consumption; low body mass 
index (BMI); family history of fracture or OP; genetic predisposition. All these 
factors should be taken into account when assessing risk of fracture to 
determine which patients require further assessment and or treatment (37,38). 
OP develops slowly over several years. It is a chronic and progressive 
disease and is the most common metabolic bone disease. An understanding of 
bone metabolism and OP mechanisms is crucial in terms of effective disease 
prevention, diagnosis, and therapy. OP diagnosis and fracture risk estimation is 
based mostly on T-scores on BMD scale. T‐score is the difference between a 
measured BMD and the average BMD in healthy young adults (39). Osteo-
porosis in postmenopausal women is defined as a T-score ≤2.5 SD (40); 
however, OP fractures might also occur among those at a moderate risk (41–
43).  
 
 
2.2. Treatment of osteoporosis 
Treatment for osteoporosis is based on using medicines that strengthen bones. 
As a chronic and progressive bone disease, long-term treatment is needed to 
control bone metabolic disruption, and patients need to adhere to treatment if it 
is to be effective and cost-effective (44,45). 
The efficacy of osteoporosis drugs ultimately depends on whether they 
reduce the risk of fractures (46). The medicines used to ameliorate osteoporosis 
are the bisphosphonates (ATC group M05BA), peptides of the parathyroid 
hormone family (ATC group H05AA), selective estrogen-receptor modulators 
(SERMs) (ATC group G03XC), and other drugs that affect bone structure and 
mineralization (strontium ranelate and denosumab) (ATC group M05BX) (47).  
The drugs used against OP have all been shown to reduce the risk of 
vertebral fractures, some have also been shown to reduce the risk of non-
vertebral fractures and those of the hip (48,49). The effects of the different 
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agents used to treat osteoporosis are summarized in Table 1, which is modified 
from Kanis et al. (47). To date no single agent has been shown to be signi-
ficantly superior in preventing fractures (50,51). The safety profile of the 
existing osteoporosis medicines have also been shown as favourable (52). There 
are several novel antiosteoporotic compounds in development with many of the 
new drugs combining efficacy with convenient administration that might 
translate into better adherence (53). 
The bisphosphonates group is the first-line OP treatment option in most 
countries and comprises orally administered alendronic acid, ibandronic acid, 
and risedronic acid, and parenterally administered pamidronic acid and 
zolendronic acid. Bisphosphonates combinations group consists of combination 
preparations of bisphosphonates with added calcium, colecalciferol, or both. 
Not all active substances classified in the WHO ATC are used in Estonia. In 
Estonia, the active substances used to treat osteoporosis are alendronic acid, 
ibandronic acid, risedronic acid, zolendronic acid, alendronic acid combined 
with colecalciferol, strontium ranelate, and denosumab (54). 
As can be seen from Table 1, regardless of the active ingredient, all the trials 
that ascertained the efficacy of an osteoporosis medicine to ameliorate the risk 
of vertebral fractures lasted at least three years and patients’ medicine intake 
was monitored to assure sufficient adherence. These trials indicated that the 
optimal treatment duration using osteoporosis medicines is at least three years, 
and sufficient adherence is necessary to obtain the results hoped for. Although 
some studies have shown self-reported improvement in patients’ quality of life 
after only one year of treatment with bisphosphonates (55), this should be con-
sidered a surrogate endpoint. 
The maximum required duration of treatment with bisphosphonates has 
recently been the subject of debate. Some authors recommend a drug holiday to 
prevent side effects from long-term use after 5 to 10 years of bisphosphonate 
treatment. Because bisphosphonates accumulate in bones and continue to 
provide some residual antifracture risk reduction it does not pose a risk. The 
duration of treatment and length of the holiday should be based on individuals’ 
fracture risk, although patients at a mild risk might stop treatment after 5 years 
and remain on holiday as long as their bone mineral density is stable and no 
fractures occur; higher risk patients should be treated for 10 years and have a 
holiday of no more than a year or two (63). Other research has shown long-term 
bisphosphonate use does not influence bone material properties, but is 
associated with adverse effects (64). 
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Monitoring the efficacy of anti-osteoporotic drugs in a real-life setting is part of 
successful osteoporosis management, as it can help identify poor-adherent from 
non-responder patients (65). Although a connection between increases in 
medicine consumption and the decrease in price of drugs has been suggested for 
other drug classes (66), specific data concerning changes in the consumption of 
osteoporosis medicines and the price of drugs is scarce. 
 
 
2.3. Drug utilization research 
2.3.1. Definition 
Drug utilization research was defined by the WHO in 1977, as “the marketing, 
distribution, prescription, and use of drugs in a society, with special emphasis 
on the resulting medical, social and economic consequences” (67). The 
discipline can be seen as a bridge between pharmacoepidemiology and health 
services research, and is closely connected to clinical pharmacology that aims to 
promote the safe and effective use of medicines (3).  
The ultimate goal of drug utilization research must be to assess whether 
using a drug therapy is rational or not. To reach this goal, methods of auditing 
drug therapy are necessary (67).  
Drug utilization can be measured in costs; the weight of active ingredients 
used; the number of packets or tablets; the number of prescriptions; and defined 
daily doses. It is valuable to use more than one type of measurement, as it 
provides researchers other aspects to investigate that might help them better 
understand drug use (3). 
 
 
2.3.2. Methods and data collection 
Drug utilization studies can be quantitative or qualitative (68). Quantitative 
studies report on the present state, developmental trends, and time course of 
drug usage; qualitative studies assess the appropriateness of drug utilization by 
linking prescription data to the reasons for prescribing (68). 
The data sources used in drug utilization research can be primary or 
secondary. Primary data is collected by an investigator specifically for research 
purposes; secondary data sources (patient files, medical records) have not been 
generated for research purposes, but can be used in the analysis of a research 
question (69). 
Data used in drug utilization research can be obtained from sales registries, 
procurement records, drug warehouse records, prescriptions, medical records, 
dispensing records, pharmacy stock accounts, health professionals, and patients 
themselves (3).  
 
 
16 
2.3.3. Units of measurement in drug utilization research 
Use of the Anatomical Therapeutic Chemical (ATC) classification system and 
the defined daily dose (DDD) as the measuring unit are the recommended 
methods in quantitative drug utilization studies. This system is widely used 
internationally, which makes cross-national comparisons possible (70). If one 
wants to perform valid and comprehensive cross-national utilization research, it 
is necessary to implement and validate ATC/DDD systems across all the 
countries in order to make the data comparable (71). 
In the ATC classification system, the active substances are divided into 
different groups according to the organ or system upon which they act, and their 
therapeutic, pharmacological, and chemical properties. Drugs are classified at 
five different levels. Drugs are first divided into fourteen main groups based on 
organ systems they affect (1st level), then pharmacological/therapeutic sub-
groups (2nd level). The 3rd and 4th levels are chemical/pharmacological/ thera-
peutic subgroups, and the 5th level is the chemical substance. The 2nd, 3rd and 4th 
levels are often used to identify pharmacological subgroups when that is con-
sidered more appropriate than dividing them into therapeutic or chemical 
subgroups (70). 
DDD is the assumed average maintenance dose of a drug per its main use in 
adults. Defined daily dose is a unit of measurement and does not necessarily 
reflect the recommended or Prescribed Daily Dose (PDD). Doses per individual 
patients and patient groups often differ from the DDD. Drug consumption data 
presented in DDD only gives a rough estimate of consumption, but not an exact 
record of the actual number of patients (70). 
Drug consumption figures should preferably be presented as DDD/1000 
inhabitants/day (DID), or when in-hospital drug use is considered, as DDD per 
100 bed days. Sales or prescription data presented in DID may provide a rough 
estimate of the proportion of the population within a defined area treated with 
certain drugs. For example, the figure 10 DID indicates that 1% of the popu-
lation receives a certain treatment. This is only correct however if the prescribed 
dose corresponds to the DDD (70). 
 
 
2.4. Medication adherence 
2.4.1. General aspects 
Adherence to medicines refers to whether a patient takes their medicines as 
prescribed (day-to-day treatment with respect to timing, dosage, and frequency). 
Following the regimen to a sufficient extent is critical to achieving a drug’s 
therapeutic effect (72). Medication non-adherence is the number one reason that 
the efficacy of medication shown in clinical trials is not achieved in real-life 
settings, and is associated with adverse treatment outcomes (6,73). Suboptimal 
medication adherence is universal across different classes of medicines (74). 
When facing a clinical situation where targets have not been reached, despite 
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substantial efforts to prescribe the most adequate therapy, non-adherence should 
be considered (75). Optimal adherence to treatment has been shown to 
substantially decrease health care costs compared to suboptimal adherence or 
almost non-existent adherence (76). 
In real-life, the majority of patients’ adherence to medicines is suboptimal 
(77), thus the cost-effectiveness of interventions is questionable as the efficacy 
of medicines is different than during clinical trials (78,79). It has been sug-
gested that adherence to medicines should be taken into account when 
evaluating the cost-effectiveness of medicines, but this is currently not done in 
the majority of cases (80). If adherence can be improved, it would help achieve 
the optimal effect of medicines and reduce the outcomes of diseases the 
medicines are meant to prevent (81). Several factors, such as age, comorbidities, 
and polypharmacy, may affect adherence and influence the outcome of 
treatments. Even a change to the appearance of medicine packaging has been 
shown to create confusion and reduce patients’ adherence (82). 
 
 
2.4.2. Primary and secondary adherence 
Adherence to medicines can be divided into primary and secondary adherence 
(83). Primary medication non-adherence (PMN) occurs when a new treatment is 
indicated, but the patient does not obtain the initial medicine prescription within 
an acceptable period of time. Secondary non-adherence measures prescription 
dispensing amongst patients who collected their first prescription (5). Secon-
dary adherence to chronic disease medicines comprises three aspects: whether 
the treatment was initiated by the patient; if medicines are taken as prescribed; 
and whether the patient persists with the treatment for a sufficient time period 
(4). The adherence stages described have different drivers and thus the reasons 
patients become non-adherent are different, and possible solutions to non-
adherence therefore must be multidisciplinary to cover all the different aspects 
of non-adherence (84). 
 
 
2.4.3. Research methods 
Aspects of secondary non-adherence to medicines have been studied quite 
thoroughly in other countries, but not in Estonia. Pre-initiation or primary non-
adherence however has not been the subject of a lot of research, due primarily 
to resource related issues. Most adherence related research is done based on 
medicine claims databases, which effectively capture dispensing data, but often 
lack information regarding how often a medicine was prescribed (85). The 
increasing use of ePrescribing systems around the world (86) enhances the 
possibilities to study PMN, as the acts of prescribing and dispensing medicines 
are recorded in the same database, or can be easily collated from two different 
databases (87). 
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Medication adherence can be approached using direct methods (e.g. mea-
suring drug concentrations in blood) or indirect methods (e.g. interviewing 
patients about their intake of medicines) (3). Direct methods require a clinical 
visit and bodily fluid to be collected, and are therefore costly and impractical in 
terms of every day adherence assessments. Direct methods are also subject to so 
called white coat adherence, meaning sampling is sparse and a patient can 
escalate their adherence before an appointment with a doctor (88). Indirect 
methods of adherence assessment can be self-reported scales or diaries, pill 
counts, prescription and dispensing databases, and electronic monitoring of drug 
intake (3). A critical review of self-reported measurements found them to be 
insufficiently precise, and in general unreliable in comparison with more 
objective tools (89). Pill counts were one of the earliest methods of adherence 
research, but these tend to overestimate the number of doses actually taken, as 
patients can easily reduce the number of tablets left in stock before checked 
upon (77). A medication event monitoring system (MEMS) is a smart medi-
cation package that records the time and date of every opening of the package. 
Adherence data resulting from the use of such packages are reliable and 
detailed. MEMS are too costly and labour intensive to use in every day practice, 
but are considered the gold standard of medication adherence measurement in 
clinical trials (90). Using prescription or dispensing databases are the gold 
standard to measure adherence in a community setting. Although they have 
their limitations, they have proved to be a valid proxy to establish patients’ 
medication adherence (91). As using a prescriptions database requires the re-
searcher to assume the prescription was also dispensed and done so on the same 
day as it was prescribed, data from a dispensing database is a better estimate of 
actual patient behaviour (3). 
 
 
2.4.4. Adherence to osteoporosis medicines 
Osteoporosis consists of chronic and progressive metabolic bone failure that 
requires long-term treatment. Previous research has shown that even a small 
decrease in the medication possession ratio (MPR), increases the risk of a hip 
fracture and the relative risk reduction of a hip fracture can be up to 60% per 
persistent patients compared to non-persistent ones (27,92), these results 
emphasize the importance of adherence to treatment to achieve optimal 
antifracture efficacy (8). The number of patients to receive treatment within a 
year after an OP-related fracture has been shown to be less than 20% (93), 
indicating there is a significant gap between the need for osteoporosis treatment 
and the actual prescribing of medicines (94). About half of the patients who do 
receive treatment adhere to it sufficiently, and only 35% persist with the treat-
ment for at least a year (7,11). Although once weekly or monthly, rather than 
daily administered medicines are associated with improved adherence, uptake is 
still suboptimal (95). The number of fractures prevented and the QALY gain 
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obtained at real-world adherence levels are only 38% and 41% respectively of 
those expected with full adherence (96). 
PMN rates vary substantially between different drug classes (97) and osteo-
porosis medicines have been shown to have some of the highest (98). This 
could be because osteoporosis does not usually cause pain or other symptoms 
until a disease induced fracture occurs, and patients tend to underestimate the 
severity of the disease, which leads to lower adherence (99). 
Improvement in adherence to osteoporosis medicines is imperative, as it 
would effectively prevent more fractures (100) and help save healthcare re-
sources from being spent on the treatment of bone fragility fractures (72). There 
are several factors that have been shown to affect patients’ medication 
adherence, but most important seem to be the doctor–patient relationship, 
patient awareness about the medicine and the disease, and also the co-payment 
of medicines (101,102). The efficacy and safety of medicines are important 
determinants of patient preferences and informed patient decision making can 
have a beneficial impact on adherence to treatment of osteoporosis (103). 
Although there is a need to stress the favourable benefit–risk ratio of osteo-
porosis medicines among patients who need pharmacological therapy, quoting 
relevant statistics to patients is not usually sufficient to allay their concerns and 
improve adherence (104). Each patient’s reasons for non-adherence tend to be 
different, and depend on individual beliefs or circumstances. Thus strategies to 
improve adherence to medicines should be individualized accordingly (105). 
Understanding patients’ preferences and incorporating them in clinical decision-
making could lead to improved care (106). The International Osteoporosis 
Foundation (IOF) has declared that there is an increasing need for strategies to 
be implemented in an appropriate health economic setting for the management 
of non-adherence for guideline development and for better reimbursement 
regulations (17,107). 
The widespread non-adherence indicates the need for policies to ensure 
safer, more effective, and cost-effective use of medication (108). While adhe-
rence research dates back several decades, there is still a considerable amount to 
be learned about adherence with regard to chronic disorders. For example, about 
the predictors of adherence to more precisely target subgroups at a higher risk 
of suboptimal adherence, and also possible interventions to improve adherence 
(109). 
 
 
2.5. Electronic prescribing 
ePrescribing is a system that facilitates the interaction between physicians and 
pharmacies, by enabling physicians to create and pass-on prescriptions 
electronically to pharmacies (110). ePrescribing in general has several benefits: 
social; health; and economic (111). ePrescribing service users have perceived it 
as easy to use and beneficial in managing their medication (112). In addition to 
the aforementioned benefits, the increase in the use of electronic prescribing 
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systems (86) enhances the possibilities to carry-out primary medication non-
adherence studies (87). 
Although it has been shown that initially primary medication non-adherence 
can increase after the implementation of e-prescribing (113), this issue was 
resolved after patients became acquainted with the system and PMN rates 
improved compared to the baseline.  
E-prescribing was introduced at the beginning of 2010 in Estonia, and it is 
one component of the Estonian eHealth system (114) that also combines the 
Electronic Health Record, Digital Registration, Digital Image, and Digital 
Prescription projects. All health care institutions, private professionals, and 
pharmacies are required to use this system, and all medical records and 
prescriptions in Estonia are centrally stored in the eHealth system (115). The 
Estonian ePrescribing system is currently one of the most comprehensive in 
Europe (12). The system is maintained and developed by the EHIF. All 
ePrescriptions are recorded at the Prescription Centre. The prescribing and 
dispensing of ambulatory medicines is done using the Prescription Centre. 
Health care professionals and pharmacies use third-party software as their 
interfaces, but they are connected to the central Prescription Centre and all 
activities concerning prescribing are saved in the central system. When an 
ePrescription is issued to a patient, they can go to any pharmacy in Estonia and 
get the medicine dispensed there. More than 99% of ambulatory medicines are 
prescribed digitally in Estonia and 100% of dispensings are saved by the 
Prescription Centre, because (the few) paper prescriptions are also inserted into 
the electronic system during dispensing (114). 
As known to author the ePrescription system saves data on: date of pre-
scribing; prescription number; patient’s identifier, age, and gender; diagnosis 
code; medicine’s active substance(s), strength(s), and dosage; instructions for 
administration; rate of reimbursement; the doctor’s name and speciality. If an 
ePrescription or paper prescription is dispensed from a pharmacy, the date of 
dispensing, package details, number of packages, name of the pharmacist and 
pharmacy, amount paid by the EHIF, patient, and the total, and comments by 
the pharmacist – if there are any – are added to the already saved data of the 
prescription. 
 
 
2.6. Summary of the literature 
The efficacy of osteoporosis medicines have been established in numerous 
clinical trials, as has the loss of health utility following an osteoporosis induced 
fracture. However, the efficacy of medicines is impaired by less than optimal 
medication adherence, which stops patients receiving the maximum effect from 
medicines. 
Worldwide, it has been established that on average only half of patients 
sufficiently adhere to prescribed medication therapy, meaning the other half 
might not gain the full benefits of a medicine, but are still susceptible to adverse 
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side-effects. Thus, assessing medication adherence is important, as interventions 
to improve adherence can be developed only if the nature and magnitude of the 
problem is measured. 
Estonia is in a rather unique position in Europe and worldwide in terms of 
medication adherence research and qualitative drug utilization research in 
general, due to the ePrescribing system that has universal coverage of doctors 
and pharmacies. This allows a very thorough assessment of patients’ behaviour 
in terms of the ambulatory consumption of prescription only medicines. 
Despite the extensive opportunities of the ePrescribing system, it has not 
been utilized much in medication adherence research in general, and adherence 
to osteoporosis medicines has never previously been studied in Estonia. The 
trend in osteoporosis induced fractures has been described by Jürisson et al. 
(27), but has not been collated to the utilization of medicines.  
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3. AIMS OF THE RESEARCH 
The present thesis is an epidemiologic study with an overall aim to analyse the 
utilization of osteoporosis medicines in Estonia and whether it correlates with 
hip fracture incidence trends. The aspects of utilization studied are to be the 
overall consumption of osteoporosis medicines, the rate of medication adhe-
rence in Estonia and whether specific patient populations with low adherence 
could be identified. 
The specific aims were: 
1. To analyse the consumption of osteoporosis medicines in Estonia and 
compare it to the consumption of the other Baltic countries; 
2. To analyse possible relationships between the consumption of osteoporosis 
medicines and the trends in osteoporosis related hip fractures; 
3. To establish primary and secondary adherence to osteoporosis medicines in 
Estonia, and explore the factors that influence adherence; 
4. To establish the average time from prescribing to dispensing of osteoporosis 
medicines, and calculate the expenditure of inefficacious treatment courses. 
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4. PATIENTS AND METHODS 
4.1. Summary of the studies 
A summary of the patients and methods included in the four studies upon which 
this thesis is based is presented in Table 2. 
 
 
Table 2. Overview of the study subjects and designs in studies I–IV 
Study 
characteristic 
Timing Population/study 
material 
Primary aim Publica-
tion 
Baltic 
comparison 
study 
2010–2014 Consumption of 
osteoporosis 
medicines in the 
Baltic countries 
based on whole-
salers’ data 
Comparison and 
analysis of con-
sumption in Estonia 
compared to other 
Baltic countries 
I 
Drug 
utilization and 
fractures study 
2004–2015 Hip fractures 
recorded in the 
EHIF database 
and consumption 
of medicines 
according to 
wholesalers’ data 
Medicine 
consumption and its 
possible relationship 
with the trend in 
osteoporosis related 
fractures 
II 
Primary 
adherence 
study 
2012–2015 8,404 patients 
(>18 years old) 
who started 
osteoporosis 
treatment 
Primary adherence to 
osteoporosis 
medicines and the 
factors influencing it 
III 
Secondary 
adherence 
study 
2001–2015 24,652 patients 
(>50 years old) 
who started 
osteoporosis 
treatment  
Secondary adherence 
to osteoporosis 
medicines and the 
factors influencing it 
IV 
 
4.2. Ethics 
The studies included in this thesis did not produce ethical concerns, as the 
patients were not identifiable to the researchers. 
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4.3. Databases 
4.3.1. Medicine wholesales database 
In the Baltic comparison study and the drug utilization and fractures study 
Estonian State Agency of Medicines’ (SAM) database was used to establish the 
total consumption of osteoporosis medicines in Estonia. SAM collects drug 
utilization data from medicine wholesalers. Every wholesaler holding an 
activity license in Estonia must submit quarterly reports to the SAM stating the 
amounts of every medicine sold. The reports cover 100% of Estonian drug 
sales. SAM compiles overall drug consumption reports using the WHO’s 
ATC/DDD classification. 
 
 
4.3.2. Health services database 
Treatment invoices are submitted to the EHIF by health care providers. The 
number of invoices submitted for hip fractures diagnosed according to ICD-10 
(S72.0–S72.2) was used to identify the number of fractures per annum in 
Estonia in the drug utilization and fractures study. Hip fractures were used as a 
proxy for all osteoporotic fractures, because a hip fracture is considered the 
most serious consequence of osteoporosis (116). Worldwide 1-year mortality 
following a hip fracture is estimated at 20–25% (117). Data was retrieved on the 
incidence of hip fractures from the health services database of the EHIF. To 
avoid duplication, only one invoice per patient per year was considered, as se-
quential fractures in one year are very uncommon. 
 
 
4.3.3. Population data 
Estonian population data was used in the drug utilization and fractures study to 
calculate hip fracture incidence. Population data in age groups for any given 
year was obtained from Statistics Estonia. Statistics Estonia publishes among 
other data the official population of Estonia (118).  
 
 
4.3.4. Prescriptions database 
In the primary and secondary adherence studies the Estonian Health Insurance 
Fund’s prescriptions database was used. The EHIF can extract data per patient 
using a unique identifier. The actual identity of the patient was concealed from 
the researchers. For every prescription, the patient’s identifier, age, gender, 
diagnosis code, prescribing doctor and their speciality, medicine and the 
number of packages dispensed, and the amount paid for the medicine by the 
EHIF and in total is stored in the database. Since 2010, with the introduction of 
ePrescribing, the database includes prescribing data in addition to dispensing 
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data. Until 2010 only dispensed prescriptions can be extracted from the data-
base. Only prescriptions reimbursed by the EHIF are included in the database. 
Valid health insurance is needed in Estonia to get osteoporosis medicines 
reimbursed. Around 95% of the population in Estonia is insured, including all 
retired persons, so the EHIF prescriptions database covers the vast majority of 
ambulatory drug consumption in Estonia (114). 
In the primary adherence study, data from the EHIF Prescription Centre on 
all prescriptions that were issued for osteoporosis medicines in Estonia from 
2012 to 2015 was extracted, with information on each patient regarding whether 
they had a prescription for an osteoporosis medicine in the prior year. Medicine 
dispensing data was extracted from the 1st of January 2012 to the 1st of March 
2016. 
In the secondary adherence study, prescriptions that were dispensed from 
Estonian general pharmacies during the years 2001 to 2015 were used to 
establish secondary adherence to osteoporosis medicines in Estonia.  
 
 
4.4. Patients 
In the drug utilization and fractures study, hip fracture incidence in Estonia was 
standardized using age distribution (5-year age groups) based on 2009 data. 
This was done because the study covered a total of 11 years and the population 
in Estonia is ageing. Men and women of all age-groups were included in the 
study, as the consumption data gathered by SAM also includes total con-
sumption of medicines. 
In the primary adherence study, all patients older than 18 years of age who 
were prescribed an osteoporosis medicine were included, regardless of 10th 
edition of the International Classification of Diseases (ICD-10) codes. Only 
patients over 18 were analysed because children probably do not make the 
decision to purchase or not purchase a medicine by themselves. Patients who 
died shortly after (≤60 days) their first prescription were excluded from the 
study. 
In the secondary adherence study, all patients aged 50+ years old who were 
dispensed at least one prescription with an ICD-10 diagnosis code referring to 
osteoporosis (M80, M81, M82, M83, M84, M85 or Q78) were included. 
Patients above 50 were included in order to be sure they were osteoporosis 
patients and not misclassified while prescribing. M80 refers to osteoporosis 
with an existing pathological fracture, M81 refers to osteoporosis but without an 
existing pathological fracture, M82 refers to osteoporosis in diseases classified 
elsewhere, M83 refers to adult osteomalacia, M84 refers to disorders of conti-
nuity of bone, M85 refers to other disorders of bone density and structure, and 
Q78 refers to other congenital bone fragility. If the patient had prescriptions 
with different diagnosis codes, then the aforementioned codes had to be present 
at least once for the patient to be included in the study (number of patients given 
in Table 2).  
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Only patients who started osteoporosis treatment were included in the 
secondary adherence study. Patients could not have osteoporosis medicines 
dispensed to them for at least a year to be defined as a new user. Data on death 
was linked to patients’ identifiers and following-up patients who died during the 
study was stopped, but other patients were followed for new prescriptions until 
the completion of the study at the end of 2015. 
 
 
4.5. Defining adherence 
4.5.1. Primary medication adherence 
Primary adherence describes whether the patient purchases the medicines from 
the pharmacy after the initial prescription and starts the treatment in the first 
place. Primary medication non-adherence (PMN) occurs when a patient does 
not purchase a medicine the first time it is prescribed. PMN was defined in the 
study as an initial prescription not being dispensed within 60 days. Prescriptions 
are generally valid for 60 days in Estonia, and the amount of any newly pre-
scribed medicine should not exceed 60 days. If the doctor and patient see that a 
medicine is effective and tolerated, refill prescriptions can be prescribed that 
cover medicine for up to 180 days and are also valid for 180 days. 
 
 
4.5.2. Secondary medication adherence 
Secondary adherence follows the behaviour of the patient after the first 
dispensing from the pharmacy until the discontinuation of treatment. The term 
adherence was used to describe the initiation of treatment, implementation of 
treatment, and persistence with treatment. This could also be referred to as 
secondary adherence because all these aspects can be monitored after a patient 
has purchased their first prescription. In our study, each aspect of secondary 
adherence was analysed separately and provided results on all of them. Suffi-
cient implementation was considered to be the theoretical medicines possession 
rate (MPR) of 80% or more doses taken over the course of treatment. The 
minimal time to take osteoporosis medicines for them to be effective is 1-year 
(119). This was considered a conservative estimate of sufficient persistence. 
Most of the clinical trials upon which osteoporosis medicines were granted 
marketing authorizations lasted three years (56,120,121). Sufficient medication 
adherence was thus defined in the context of this study as a patient taking 80% 
or more medicine doses and persisting with such implementation for one to 
three years. 
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4.5.3. Time to purchase 
In the primary adherence study, the time between prescribing and dispensing 
was also analysed, and compared the average time of purchasing initial pre-
scriptions to that of all prescriptions of osteoporosis medicines. As secondary 
prescriptions can be prescribed three refills at a time, it was calculated when the 
initial amount of medicine dispensed ran out, and set a potential dispensing date 
for the next prescription accordingly. In reality however, patients can purchase 
all three refill prescriptions at once, which means that their actual dispensing 
time is negative compared to what would be expected, as they are dispensed 
before the previous amount of purchased medicine is depleted. 
 
 
4.5.4. Treatment gaps 
In the secondary adherence study, gaps in treatment or so called “drug holidays” 
were also analysed. A gap was considered to be 90 to 180 days after the amount 
of medicine already dispensed to the patient should have been used up and no 
refill prescription was given. A gap that lasted longer than 180 days was con-
sidered the end of treatment and if the same patient started treatment again later 
in the study, it was considered a new treatment course. 
 
 
4.6. Data analysis 
In the drug utilization and fractures study and the secondary adherence study 
the Joinpoint Regression Program, Version 4.3.1.0 was used for trend analysis. 
Joinpoint is statistical software used to analyse trends. It uses joinpoint models 
to test if a trend change is statistically significant. Results of these tests are 
presented as the average annual percent change (APC) over a year. The tests of 
significance use a Monte Carlo Permutation method (122). In both studies, p-
values less than 0.05 were considered statistically significant.  
Potential relationships between the consumption of osteoporosis medicines 
and the average price of a daily dose was assessed using Spearman’s correlation 
coefficient in the drug utilization and fractures study, as both potential indica-
tors were non-normally distributed. 
In the Baltic comparison study, regression lines were compared with 
STATGRAPHICS Centurion XVII Version 17.1.12. This was done to establish 
whether there were differences in the trends of osteoporosis medicines con-
sumption between the Baltic countries. 
In the primary and the secondary adherence studies, multiple logistic regres-
sion analyses were performed using Stata v12 and v13 (StataCorp LP), respec-
tively. Multiple logistic regression analysis was used to compare primary and 
secondary adherent or non-adherent patients per socio-demographic background 
variable. Statistical significance was set at p-values less than 0.05. 
Microsoft Excel was used as the main tool for data management, descriptive 
analysis and graph design (other than specified above) in all the studies.  
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5. RESULTS 
5.1. Trends in the utilization of osteoporosis medicines and 
hip fractures 
5.1.1. Utilization of osteoporosis medicines in Estonia and  
in the Baltic and Nordic countries 
The trend in the consumption of osteoporosis medicines from 2004 to 2015 in 
Estonia can be divided into two different periods (Figure 1). From 2004 to 2009 
the increase was very steep, with an annual average of 41.2% (p<0.05). During 
this period consumption increased from 0.8 DID to 3.9 DID, an almost 5-fold 
increase. From 2009 to 2015 consumption plateaued, with a statistically non-
significant positive trend. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The actual and modelled trend of consumption of osteoporosis medicines in 
terms of the number of defined daily doses per 1000 inhabitants per day in Estonia from 
2004 to 2015. 
 
 
The consumption of all osteoporosis medicines was 4.8 DID in Estonia in 2015. 
This means that 4.8 of every 1,000 Estonian inhabitants consumed an average 
dose of an osteoporosis medicine every day. Considering that the population of 
Estonia was approximately 1,315,000 in 2015, this would translate to an 
estimated 6,300 patients. 
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When comparing Estonian consumption with that of the other Baltic 
countries, then can be seen that the consumption of osteoporosis medicines was 
rather similar in the Baltic countries in 2014: 5.2 DID in Latvia, 3.3 DID in 
Lithuania, and 4.6 DID in Estonia. The trends in consumption were also rather 
similar in the Baltic countries from 2010 to 2014 (Figure 2). Consumption 
increased from 2010 to 2013 and was then followed by a small decrease in 
2014. An overall increase only occurred in Latvia, with consumption increasing 
from 4.2 DID to 5.2 DID. In Estonia, consumption stayed at the same level of 
4.6 DID and there was a slight decrease in Lithuania from 3.4 DID to 3.3 DID. 
The average annual changes were +0.3% in Estonia, +5.9% in Latvia, and  
-0.8% in Lithuania. The slight differences in trends between countries were 
statistically non-significant, with a p-value of 0.41 between Estonia and Latvia, 
0.46 between Estonia and Lithuania, and 0.24 between Latvia and Lithuania. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The consumption of osteoporosis drugs (ATC group code M05B) in the 
Baltic countries from 2010 to 2014, in terms of the amount of defined daily doses per 
1000 inhabitants per day. 
 
 
In the Baltic countries, the choice of active substances per each country did not 
change much from 2010 to 2014 (Figure 3). Only the consumption of 
denosumab and its share of the total consumption of osteoporosis medicines 
increased in all the countries. This was highest in Lithuania, with denosumab 
consumption increasing from 0.0 DID in 2010 to 0.8 DID in 2014. In Estonia 
the consumption of denosumab was 0.4 DID by 2014, which is approximately 
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500 patients. In Latvia the consumption of denosumab was lowest, with 0.2 
DID in 2014. The consumption of bisphosphonates remained stable in all the 
countries. The consumption of strontium ranelate decreased in Lithuania and 
Estonia, and stayed the same as in 2010 in Latvia, following the restriction in its 
use by the European Medicines Agency in April 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The consumption of drugs against osteoporosis (ATC group M05B) in the 
Baltic countries from 2010 to 2014 expressed as the proportion of the different active 
substances. 
 
 
When comparing the share of different active substances used in the Baltic 
countries, Estonia stands out with its high use of the combination of alendronic 
acid and colecalciferol, which constituted almost 60% of total consumption of 
drugs against osteoporosis in 2014. Other active substances that were com-
paratively more used were ibandronic acid and plain alendronic acid, which 
consisted of 14% and 10% of the market share, respectively. In Latvia, the most 
used active substance was risedronic acid, which accounted for 40% of the total. 
The combination of alendronic acid and colecalciferol and plain ibandronic acid 
amounted to 1.3 DID and 1.1 DID, respectively. The most used active substance 
in Lithuania in 2014 was ibandronic acid, with 26% of the total (0.9 DID). The 
second most used was denosumab, with 25% of the total (0.8 DID). 
When comparing the consumption of osteoporosis drugs in Estonia to that of 
the Nordic countries (Denmark, Finland, Norway, and Sweden), the average 
consumption in the Nordic countries was 2.5-fold higher than in Estonia (12.0 
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DID and 4.6 DID, respectively) in 2015 (Figure 4). The highest consumption 
was in Denmark, with 18.4 DID. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The total consumption of osteoporosis medicines in Estonia and the Nordic 
countries in 2015, expressed in defined daily doses per 1000 inhabitants per day and the 
average consumption of the Nordic countries. 
 
 
5.1.2. The price of osteoporosis medicines 
The average price of a daily dose of osteoporosis medicine moved in the 
opposite direction to consumption from 2004 to 2015 (Figure 5). The average 
price decreased by 16.9% (p<0.05) on average every year from 2004 to 2009. 
From 2009 to 2015 the decrease was 4.7% and the trend non-statistically 
significant. 
The correlation between the consumption of osteoporosis medicines and the 
average price of a daily dose was -0.94 (p<0.001) from 2004 to 2015. The 
correlation for the period 2004 to 2010 was -0.95 and for the period 2011 to 
2015 it was -0,26. 
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Figure 5. The actual and modelled trends in consumption of osteoporosis medicines, in 
terms of the number of defined daily doses per 1000 inhabitants per day (DID) and the 
average price of an osteoporosis medicine (ATC group M05B) daily dose in euros in 
Estonia from 2004 to 2015. 
 
 
5.1.3. Trend in hip fractures in Estonia 
There were around 1,500 hip fractures every year in Estonia from 2004 to 2015. 
Table 3 presents the standardized rate of hip fractures in 5-year age groups of 
patients over 50 years old for the years 2004 to 2015. 
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The trend in standardized hip fracture incidence rates from 2004 to 2015 can be 
divided into two periods. From 2004 to 2010 the rate of hip fractures increased 
on average 1.2% every year. The highest fracture rate was in 2009, with 123.2 
fractures per 100,000 persons. The trend was not statistically significant. From 
2010 to 2015 there was a statistically significant 4.5% (p<0.05) average annual 
decrease in standardized incidence rates of hip fractures (Figure 6). The results 
of table 3 are discussed in detail under point 6.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The standardized incidence rate and modelled trend of hip fractures (ICD-10 
codes S72.0–S72.2) per 100,000 persons in Estonia from 2004 to 2015. 
 
 
5.2. Medication adherence 
5.2.1. Primary Adherence 
5.2.1.1. Patients 
8,404 patients were prescribed osteoporosis medicines for the first time in 
Estonia from 2012 to 2015, and were included in our study (Figure 7). 7,834 
(93.2%) of the patients were female and 570 (6.8%) male. 
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Figure 7. Identification of the primary medication adherence study cohort. 
 
 
5.2.1.2. Primary medication non-adherence 
1,100 (13.1%) patients out of the 8,404 did not purchase their first prescription 
within 60 days of prescribing. 462 patients (42.0% of the PMN patients, or 
5.5% of the total number of patients) failed to purchase the first prescription, 
but did purchase a subsequent prescription. The median time for these patients 
between the first prescription and an actual dispensing was 92 days. 638 
patients (7.6%) never purchased medication. Some of those patients (n=82) had 
more than one prescription that was not dispensed. For example, 3 patients had 
5 prescriptions but did not purchase any of them. 4 patients had 4 prescriptions 
that all expired without being dispensed and 18 patients had 3 expired 
prescriptions with no dispensing.  
 
 
5.2.1.3. Patient characteristics associated with  
primary medication non-adherence 
The characteristics of patients who were primary adherent or primary non-
adherent are presented in Table 4. Gender did not influence the probability of a 
patient being primary adherent or non-adherent (p = 0.813). Patients who had a 
prior fracture (M80) were more likely to purchase their first prescription than 
All patients prescribed osteporosis 
medicines in Estonia from 2012–2015
(N=15,629)
Had an osteoporosis medicine 
prescription within one year prior 
to the study period
n=7,124
First prescription of an 
osteoporosis medicine during the 
study period
n=8,404
Prescription not dispensed 
within 60 days (primary non-
adherent)
n=1,100
Prescription dispensed within 
60 days (primary adherent)
n=7,304
Exclusions
- aged under 18 years old (n=28)
- died less than 60 days after first  
prescription (n=73)
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patients with osteoporosis but no fracture (M81) or patients with other 
diagnoses. Initial prescriptions by orthopaedists or rheumatologists were more 
frequently dispensed than those issued by general practitioners. Differences in 
the purchase proportion of prescriptions by other specialists were non-signifi-
cant compared to GPs’. Patients started on strontium ranelate or denosumab 
were more likely to be primary non-adherent compared to patients started on 
plain alendronic acid. There were no significant differences between the other 
active substances. Younger patients were more likely to be primary non-
adherent than older patients, with the odds to be adherent increasing 7% (95% 
CI 3-10, p-value<0.001) with every 5 years of age. 
 
 
Table 4. Characteristics of primary adherent and primary non-adherent patients 
  
Primary 
adherent 
(n=7,304) % 
Primary 
non-
adherent 
(n=1,100) % 
Adjusted 
OR 95% CI p-value 
Gender 
Male 488 85.8 81 14.2 1 (ref) 
Female 6,816 87.0 1,019 13.0 0.97 0.75 1.25 0.813 
Diagnosis 
M80 4,527 88.9 568 11.2 1 (ref) 
M81 2,395 85.2 415 14.8 0.78 0.68 0.90 0.001 
Other 382 76.6 117 23.5 0.46 0.36 0.59 <0.001 
Doctor’s speciality 
Orthopaedic 
surgeon 1,000 88.4 132 11.7 1.69 1.35 2.12 <0.001 
GP 1,768 83.9 340 16.1 1 (ref) 
Rheumatologist 3,500 88.5 453 11.5 1.47 1.25 1.71 <0.001 
Other 1,036 85.6 175 14.5 1.19 0.97 1.46 0.093 
Active substance 
alendronic acid  990 85.0 175 15.0 1 (ref) 
ibandronic acid  835 85.8 138 14.2 1.04 0.81 1.33 0.751 
risedronic acid 324 86.6 50 13.4 1.08 0.77 1.52 0.663 
zoledronic acid 32 72.7 12 27.3 0.58 0.29 1.18 0.133 
alendronic acid 
and colecalci-
ferol 4,676 88.2 625 11.8 1.13 0.93 1.36 0.215 
risedronic acid, 
calcium and 
colecalciferol, 
sequential  0 0.0 1 100.0 - 
eptotermin alfa 0 0.0 1 100.0 - 
strontium 
ranelate 177 80.5 43 19.6 0.67 0.46 0.98 0.037 
denosumab  270 83.1 55 16.9 0.71 0.50 1.00 0.050 
Age 
mean (sd) 
70.3 
(10.3) 68.4 (12.2) 1.07* 1.03 1.10 <0.001 
* Odds ratio presented per every 5-year change in age 
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5.2.1.4. Time to dispensing 
3,340 (45.7%) of the 7,304 primary adherent patients purchased their first 
prescription on the same day it was prescribed. 5,873 (80.4%) purchased it 
within a week, 89.0% within two weeks, and 95.0% less than 25 days from the 
date of the prescription (Figure 8). After 25 days the dispensing of medicines 
was occasional with no peaks near the end of prescription expiration date. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The number of days between prescribing and dispensing of first prescriptions 
to patients who started osteoporosis treatment in Estonia during 2012 to 2015. 
 
 
Of all osteoporosis prescriptions purchased in Estonia from 2012 to 2015 
(148,263 prescriptions), 14.7% were dispensed on the day of prescribing and 
66.3% before the prior prescription was depleted or within a week after a new 
prescription was issued (Figure 9). 
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Figure 9. Number of days from prescribing to dispensing of all osteoporosis medicine 
prescriptions issued in Estonia from 2012 to 2015. 
 
 
5.2.2. Secondary adherence 
5.2.2.1. Patients 
In total, 25,480 new patients received osteoporosis medicines – at least one 
prescription – in Estonia from 2001 to 2015. 825 were under 50 and left out of 
the study. 3 patients were dispensed their first prescription after the patient had 
died and these patients were also left out of the study. Of the 24,652 patients 
included, 23,091 were female (93.7%) and 1,564 male (6.3%). The patients’ age 
distribution is presented in Figure 10. 
 
 
 39 
  
Figure 10. Age distribution of patients aged 50+ years old who started treatment using 
osteoporosis medicines (ATC group M05B) in Estonia from 2001 to 2015. 
 
 
5.2.2.2. Initiation of treatment 
4,636 (18.8%) of the 24,652 patients who started treatment with osteoporosis 
medicines were dispensed only one prescription. The number of patients 
starting treatment per year increased steadily from 2001 to 2009, and declined 
from 2010 to 2015. The percentage of patients who were dispensed only one 
prescription and not more, showed a 2.4% annual increase throughout the study, 
which was statistically significant (Figure 11). 
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Figure 11. The yearly number of patients who started treatment with osteoporosis 
medicines and the modelled trend of patients who were dispensed only one prescription. 
 
 
5.2.2.3. Implementation of treatment 
44.2% of patients had a MPR ≥80% throughout their follow-up period. 18.8% 
of patients purchased only one prescription and 37.0% of patients had a MPR 
less than 80%. The share of patients with a MPR over 80% increased from 2001 
to 2014. At the beginning of the 2000s, 60–70% of patients were not imple-
menting their treatment sufficiently, but this decreased to approximately 20% 
by 2014 (Figure 12). The increase in the number of patients with sufficient 
implementation can be divided into two periods: from 2001 to 2005, and 2005 
to 2014. During the first period, the annual increase was 29% and during the 
second 5%. 
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Figure 12. Implementation of osteoporosis treatment in Estonia according to the year 
the treatment was initiated. Data presented as the percentage of patients who had a 
medication possession ratio (MPR) ≥80%, <80%, and those who were dispensed only 
one prescription, and the modelled annual change in the percentage of patients with a 
MPR ≥80%. 
 
 
5.2.2.4. Persistence with treatment 
8,922 (36.2%) patients had sufficient implementation (MPR ≥80%) and 
persisted with treatment for at least 1 year. 19.8% of patients had a continuous 
treatment course that lasted for at least 3 years and had a MPR ≥80% over the 
course. 299 patients persisted with osteoporosis treatment for longer than 10 
years with good implementation (Figure 13). 
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Figure 13. The percentage of patients with a MPR ≥80% who persisted with treatment 
over a given number of years. 
 
 
5.2.2.5. Gaps and restarters 
2,483 patients took short “drug holidays” during their treatment. 4,555 patients 
restarted treatment after stopping for a longer period of time, and 2,360 patients 
had both types of gap: drug holidays and restarted treatment. 47.0% of the 
patients who purchased at least 2 prescriptions had short or long gaps in their 
treatment. 17,737 patients (72.0% of the total number of patients) had only one 
treatment course and 4,636 (26.1%) were dispensed only one prescription. 
19.5% of patients started treatment twice and 8.5% had 3 or more initiations of 
treatment. 2 patients started treatment 9 times during the 15-year time period. 
 
 
5.2.2.6. What drives secondary adherence 
Patient characteristics that relate to medication adherence are presented in Table 
5. Females were 2.4-times more likely (p<0.001) than men to have a treatment 
course longer than one year with good implementation. Age also seemed to be a 
factor that influenced adherence. When patients aged 50–59 were taken as the 
baseline, the probability to be adherent increased for the age group 60–69 by 
20% (p<0.001) and for 70–79 by 12% (p=0.004), but decreased for patients 
80+. The results were similar when we calculated statistical differences at 3-
year persistence. Patients who had a fracture when they were first prescribed 
osteoporosis medicines (ICD-code M80) were more likely to be adherent to 
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treatment than those who did not initially have a fracture (ICD-code M81). 
When treatment was initiated by a general practitioner, the probability of the 
patient being adherent was lower than when treatment was started by a 
specialist. The number of different medicinal products or active substances used 
from ATC group M05B increased the probability of being adherent with every 
additional product and active substance. 
 
 
Table 5. Factors related to the probability of having a MPR ≥80% for at least 1 or 3 
years. 
 
  
  
MPR ≥80% for  
at least 1 year 
(OR, CI 95%, p-value) 
MPR ≥80% for  
at least 3 years 
(OR, CI 95%, p-value) 
Gender Male 1 1 Female 2.37 (2.09–2.69) p<0.001 2.72 (2.28–3.25) p<0.001 
Age in years 
50–59 1 1 
60–69 1.20 (1.11–1.30) p<0.001 1.29 (1.18–1.43) p<0.001 
70–79 1.12 (1.04–1.21) p=0.004 1.18 (1.07–1.30) p=0.001 
80–89 0.89 (0.80–0.98) p=0.014 0.77 (0.69–0.88) p<0.001 
90+ 0.45 (0.29–0.70) p<0.001 0.18 (0.07–0.44) p<0.001 
Diagnosis M80 1 1 
M81 0.87 (0.83–0.92) p<0.001 0.86 (0.81–0.92) p<0.001 
Doctor’s 
speciality 
General 
Practitioner 1 1 
Orthopedic 
surgeon 1.13 (1.02–1.26) p=0.018 0.97 (0.86–1.11) p=0.696 
Rheumatologist 1.47 (1.38–1.56) p<0.001 1.33 (1.24–1.43) p<0.001 
Other 0.88 (0.80–0.96) p=0.003 0.87 (0.78–0.96) p=0.009 
Number of 
different 
preparations 
dispensed 
For every 
additional 
medicinal 
product  
1.91 (1.86–1.97) p<0.001 2.24 (2.17–2.31) p<0.001 
Number of 
different 
active 
substances 
dispensed 
For every 
additional active 
substance 
2.05 (1.97–2.13) p<0.001 2.46 (2.36–2.57) p<0.001 
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5.2.2.7. Expenditure on medicines 
From 2001 to 2015, a total of €14,172,142 was spent on osteoporosis medicines 
per patients who started treatment in Estonia. €8,247,370 was paid by the EHIF 
and €6,647,697 by the patients. Of the 14 million, €8,471,773 (59.8%) was 
spent on medicines per patients who were adherent for at least one year. 
€5,700,369 (40.2%) was spent on the treatment of patients who did not have 
sufficient implementation, did not persist long enough, or who purchased only 
one prescription. The study period was also divided into two periods: before 
2007 when osteoporosis medicines did not have higher reimbursement and after 
2007 and these periods were analysed separately. The percentage of expenditure 
on possibly ineffective treatment during the pre-reimbursement period was 
70.1% in total. 72.1% of money spent by EHIF was for ineffective treatment 
and 69.0% spent by patients. The amount paid by the patients was 1,939,517€ 
(66.4%) and by EHIF 982,737€ (33.6%). During the period after 2007 32.5% of 
the expenditure was for ineffective treatment. During this period 30.2% of 
expenditure by EHIF was for ineffective treatment and 36.6% of the patients’ 
expenditure. The amount paid by the patients from 2007 onward was 
3,984,510€ (35.4%) and by EHIF 7,264,632€ (64.6%).  
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6. DISCUSSION 
6.1. Utilization of osteoporosis medicines 
People at risk from osteoporosis in Estonia is estimated at 5.8% of the total 
population (17). This translates to approximately 75,000 to 80,000 people 
whose bone quality might be affected by osteoporosis and are therefore at risk 
of bone fractures (107). According to our studies, osteoporosis ameliorating 
drugs were received daily by approximately 6,300 patients in Estonia in 2015. 
This is less than 10% of the total number of patients at risk of osteoporosis. In 
addition, comparison with the Nordic countries suggests the consumption of 
osteoporosis medicines in Estonia should be higher, as Estonian consumption 
was 2.5-fold lower in 2015 than the Nordic average. Similar conclusions are 
reported in an EU osteoporosis report, which also suggested that changes in 
healthcare policy concerning osteoporosis is warranted (107). 
During the 1990s, no medicine with evidenced efficacy against osteoporosis 
was used in Estonia; the consumption of bisphosphonates started at the 
beginning of the 2000s (123). Owing to the high price of these medicines and 
no higher reimbursement by the EHIF, consumption was still very low during 
the first half of the 2000s. Consumption derived from the wholesale statistics 
does not reflect all the patients who received treatment against osteoporosis, as 
there were several clinical trials of medicines in Estonia during the first half of 
the 2000s. This helped patients get access to medicines they would not 
otherwise be able to afford. The number of trials that included patients from 
Estonia was around 20. Probably the impact of clinical trials was also greater 
than just the patients who got the study drug, as patients in the placebo arm 
were put on vitamin D and calcium supplements, and knowledge of osteo-
porosis and the possible preventive measures was increased amongst both 
doctors and patients.  
The consumption of osteoporosis medicines in Estonia more than doubled in 
just two years after 2007. The reasons for this were the EHIF providing a 75% 
reimbursement (90% if the patient was older than 63) for patients with a prior 
fracture and DXA T-score ≤ –2.5SD, and the first generic medicines coming to 
market, which brought down the cost of some medicines. Before 2007, 
bisphosphonates were reimbursed at 50%, but to a limit of €12.8 per pre-
scription. The price of bisphosphonates exceeded this limit considerably. As the 
75% reimbursement class does not have an upper limit that the EHIF will pay 
for a prescription, the medicines got much cheaper for patients. 
From the beginning of the 2000s until 2015 there was a general increasing 
trend of consumption of all types of medicines in Estonia (54). This was due to 
changes in people’s lifestyles and the aging of the population (124), which 
made an increase in the consumption of medicines imperative. The consumption 
of osteoporosis drugs also increased rapidly in the 2000s, but remained stable 
from 2010 to 2015. This is supported by the opinion of Estonian GPs and 
pharmacists that the knowledge of patients about osteoporosis increased during 
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the same period, which increased adherence to medicines, and thereby the 
consumption of medicines (125). As the price of medicines, which is also an 
important factor that influences consumption, did not decrease from 2010, the 
increase in consumption stopped. Regarding chronic conditions, increased drug 
utilization can reduce expenditure on related healthcare services when it is 
driven by improved adherence to guidelines-based therapy (126). Studies 
carried out in Europe investigating the consumption of osteoporosis drugs have 
shown continual increases (127). In the US however, the consumption of 
osteoporosis drugs seems to be decreasing (128). 
The most used preparation in Estonia during 2014 was the combination of 
alendronic acid and vitamin D, which constituted 59% of total antiosteoporotic 
medicine consumption. Although the cheapest orally administered product was 
ibandronic acid at €0.25 per DDD, its market share was still only 14% in 2014. 
The combination of alendronic acid and vitamin D was the most expensive of 
the oral bisphosphonates at €0.51 per DDD, meaning it cost twice as much as 
the cheapest bisphosphonate ibandronate. As the combination product is 
subsidised and the plain vitamin D products are not, then out-of-pocket payment 
is lower for the patient per the combination product than buying plain 
bisphosphonate and vitamin D separately. This explains the high use of the 
combination product as a proportion of the total of osteoporosis drugs. 
Although a combination product of calcium and vitamin D is also reimbursed to 
osteoporosis patients the patients for some reason still preferred to take the 
combination preparation and probably added calcium separately.  
Overall wealth in Estonia is substantially lower than the EU average and 
expenditure on healthcare out of the GDP is less than optimal. As a result, the 
co-payment for patients is higher in Estonia and many patients cannot afford to 
pay for their medicines. Also, the reimbursement regulations for osteoporosis 
ameliorating drugs have not changed in Estonia and only patients with a 
fragility fracture and DXA T-score under –2.5SD get medicines reimbursed at a 
rate of 75% or 90% if they are older than 63. This translates into generally low 
consumption of osteoporosis medicines in Estonia. 
 
 
6.2. The price of medicines 
The trends of overall consumption of osteoporosis medicines and the average 
daily dose price of medicines moving in opposite directions suggests that 
offering reimbursement to patients at risk of a fracture because of decreased 
bone mass, but without an actual fracture, might help to further increase the use 
of osteoporosis medicines in Estonia. As discussed before the number of 
patients taking osteoporosis medicines in Estonia cannot be regarded as 
sufficient, as the number of patients at risk of a fracture is substantially higher 
than the number of patients using medicines that help to reduce that risk. 
 
 
47 
6.3. Trend in hip fractures 
Urbanization, lack of physical exercise, an unhealthy diet, and smoking are the 
most important factors increasing fracture risk, and thus fracture trends were 
expected to increase in developed countries (17). An increase in the standar-
dized incidence rate of hip fractures was observed in our study from 2004 to 
2009, similar to what was reported before by Jürisson et al. (27). From 2010 the 
rate started to decrease. This is similar to what has been reported in most 
countries where standardized incidence of fractures has been studied (25). The 
change in the trend occurred earlier in western and northern European countries 
compared to Estonia. For instance, in Scandinavia the decrease started in the 
1990s (26). The unexpected declines in fractures are speculated to be the result 
of several different factors. One important aspect is the increasing use of osteo-
porosis drugs, but also is the growth in average BMI – as body weight in-
creases, so does the weight of bones – in reducing incidence of fractures. Im-
provement of general health, the declining numbers of smokers, and campaigns 
to prevent falls are also named as reasons for the declining trends in osteo-
porosis induced fractures (129,130). If these aspects are put into an Estonian 
context, then the percentage of women with a BMI over 25 was 70.0 in the 
1990s and 71.5 in the 2000s, thus a substantial rise in the percentage is not seen 
(131). The number of smokers amongst women over 55 has increased in 
Estonia, as in the 1990s 19% stated themselves to smoke and 34% did so in the 
2000s (131). It seems that in Estonia the possible explanations per the 
decreasing trend are more likely to be the increased use of osteoporosis medi-
cines and improvement in general health, as we have not had specific nation-
wide fall prevention campaigns. Jürisson et al. (27) also hypothesized that the 
decrease in the osteoporosis related fracture rate is due to increased use of 
bisphosphonates, a reduction in falls-related comorbidity which in turn is the 
result of improved general health, and prevention and better treatment of other 
chronic diseases. The claim of better general health in Estonia can be supported 
by the life expectancy of a 65 year old woman in Estonia increasing from 17.9 
to 20.3 years (2.4 years in total) between 2004 and 2015 (131). 
The quick increase in consumption of osteoporosis medicines in Estonia was 
followed by a decrease in the standardized incidence of hip fractures rate. An 
increase in consumption and decrease in fractures has been demonstrated in 
earlier studies (28,116). A declining trend in fractures has been shown to be 
reversible with a reduction in the consumption of osteoporosis drugs (30). Since 
2010 the consumption of osteoporosis drugs levelled-off in Estonia. Utilization 
of osteoporosis medicines is only one driver of changes in the incidence of hip 
fractures (129), but if the stop in the increase of the utilization of osteoporosis 
drugs in Estonia will have an effect on the trend in fractures remains to be seen. 
Our study indicates that the utilization of osteoporosis medicines has an effect 
on the rate of osteoporosis related fractures and consumption of medicines is 
strongly influenced by the price of medicines. 
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6.4. Primary adherence 
6.4.1. Primary medication non-adherence 
The introduction of electronic prescribing has made it easier to assess primary 
adherence to medicines, which was difficult before because of a lack of data 
(83). The percentage of patients who are prescribed but never purchase their 
medicines varies in studies from 2.4 to 30.7%, depending on how primary non-
adherence is defined and which drug classes are included in the study (132). 
Primary non-adherence was defined as a patient not being dispensed their initial 
prescription within 60 days after prescribing. As a prescription is valid in 
Estonia for 60 days, this meant that if the initial prescription expired without 
being dispensed, the patient was considered primary non-adherent. In the study 
osteoporosis medicine primary non-adherence was found to be 13.1%. This is 
an average result when all medicine classes are compared (133). However, rates 
of primary non-adherence per osteoporosis medicines have been shown to be 
one of the highest. The rates for osteoporosis medicines have been reported to 
be from 22.4–37.0% (98,134–136). Our result suggests a substantially lower 
rate of PMN than found before. The most recent and largest study to date by 
Reynolds et al. reported primary non-adherence to bisphosphonates to be almost 
30% (136). The number of patients included in our study was similar to 
Reynolds et al.’s study and a 60-day window was used in both studies to 
establish primary non-adherence. In Reynolds et al.’s study, only women over 
55 were included, but in the current study all patients over 18 years old were 
included. Owing to the nature of the disease, the number of men (6.8%) and 
patients under 55 (3.1%) was small in our study. Therefore, the different patient 
selection criteria are probably not the cause for the difference in results. The 
Estonian electronic prescribing system is one of a few in Europe and globally 
where there is one central prescriptions system in a country and all doctors and 
pharmacies are connected to that system. After a prescription is issued the 
patient can purchase the drug from any pharmacy of their choice in Estonia. 
There are digital prescribing systems where a patient can use some or name 
certain pharmacies from where they can purchase their medicine with a digital 
prescription (12). In Reynolds et al.’s study, patients could only use certain 
pharmacies from where they could buy their medicine and if they used other 
pharmacies they would be misclassified as primary non-adherent. The fact that 
pharmacies are very easily accessible in Estonia (there is a pharmacy in most 
healthcare and shopping centres), could be one of the reasons for the low rate of 
primary non-adherence. 
Setting the rule that a prescription must be dispensed within 60-days for a 
patient to be considered primary adherent is arbitrary. A patient could start 
treatment even if they fail to purchase the initial prescription. In our study, 462 
(42.0%) of the 1,100 primary non-adherent patients started treatment with a 
subsequent prescription, and half of those patients did it less than 3 months after 
the first prescription was issued. As patients probably receive further coun-
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selling and motivation from their doctor with the next prescription, that 40% of 
patients initiated treatment after this additional visit, suggests that patient 
behaviour can be turned in the right direction with further information and 
support. Our result also indicates that concentrating only on whether the initial 
prescription is dispensed overestimates the proportion of patients who fail to 
initiate treatment. 
 
 
6.4.2. Characteristics influencing primary adherence 
Older patients were found to be more primary adherent than younger patients in 
Estonia. This result is opposite to that found by Reynolds et al. (136). As 
patients older than 63 get medicines reimbursed at a higher rate (90%) than 
patients under 63 (75%) in Estonia, this could be one of the reasons that older 
patients have better primary adherence. Treatment initiation has been shown to 
be influenced by the price of medicines (137). Denosumab is administered once 
every six months and has been shown to result in better secondary adherence 
than oral bisphosphonates (138), but it is also more expensive and our study 
showed that primary medication adherence is lower with denosumab than with 
alendronic acid. This means potential PMN issues must be addressed by the 
doctor when initiating treatment with denosumab. The diagnosis code and 
prescribing doctor’s speciality where also factors that influenced PMN. Patients 
with a prior fracture were more likely to purchase initial prescriptions than 
patients without a fracture. In addition, patients whose treatment was started by 
orthopaedists or rheumatologists had better initiation. However, these results are 
interconnected as patients with fractures are more frequently prescribed by 
specialists. 
 
 
6.4.3. Time to dispensing 
Previous research has reported that 64% of osteoporosis medicine prescriptions 
are purchased within a week (136). The dispensing of other drug classes have 
been shown to be faster, with 65% purchased on the same day and 89% within 
30 days (139). Our results showed faster dispensing compared to earlier osteo-
porosis drug studies and were more similar to the results of other drug classes. 
80% of prescriptions were purchased within a week of prescribing and 89% 
were purchased within two weeks in our study. If all the osteoporosis drug 
prescriptions of all patients during 2012 to 2015 were investigated, then almost 
70% of prescriptions were dispensed before the amount purchased with the 
prior prescription was depleted or less than a week from the prescribing of a 
new prescription. When a doctor prescribes or when a pharmacist dispenses 
medicines, they see which prescriptions are active to the patient in the 
Prescription Centre. According to our study, if they happen to come across 
prescriptions that are older than a week and are still active, they should discuss 
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possible adherence issues with the patient. Proactive interventions by pharma-
cies have been shown to improve adherence (140). 
 
 
6.5. Secondary adherence 
6.5.1. Initiation 
The number of patients who started osteoporosis treatment increased rapidly at 
the beginning and middle of the 2000s, peaking in 2009. Then the number of 
new patients started to decrease. The fast increase can possibly be explained by 
the drugs becoming more affordable to patients, with generic medicines 
entering the market and the EHIF providing 75% and 90% reimbursement to 
patients with a prior fracture (114). A crucial factor that influences whether a 
patient starts treatment and is adherent is how much the patient knows about the 
disease and the treatment. Estonian doctors and pharmacists have assessed the 
knowledge of patients to have improved over time (125). The decline in new 
users following the swift increase is harder to explain. Also, the percentage of 
patients who purchased medicine with only one prescription increased, which is 
opposite to what would be expected when medicines become cheaper. This 
indicates that the affordability of medicines is probably not the main factor 
hindering treatment initiation in Estonia. 
If we add up the percentage of patients who never purchased their medicine 
from the PMN study and the patients who purchased medicine with only one 
prescription in the secondary adherence study we get a total of approximately 
one fourth of patients who do not initiate treatment although a physician has 
seen it necessary and prescribed a medicine. The study results are not directly 
comparable though as we used a little bit different inclusion criteria in the 
studies but it gives us a rough idea of the phenomena.  
 
 
6.5.2. Implementation 
A MPR ≥80% is most often used as the threshold of sufficient implementation 
of osteoporosis treatment, as it has been shown to be optimal for the treatment 
to be effective (141). In Estonia, 44.2% of patients had a MPR ≥80% during at 
least one of their treatment courses. Implementation of osteoporosis treatment 
has previously been reported to be from 46% (142) to 95% (143). Typically, 
daily dosing regimens have lower implementation compared to weekly or 
monthly regimens (144), and higher implementation has been shown when 
including only persistent patients in the study. Studying persistent patients gives 
better results, because patients who have already taken medicines for a long 
period are also usually more careful to take their medicines at the correct dosing 
interval. All osteoporosis medicines and all starting patients were included in 
our study, but nonetheless the result that a MPR ≥80% was achieved by only 
44.2% of patients is still one of the lowest results seen in osteoporosis medicine 
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adherence studies. This can probably be explained by our untypically long study 
period and that new patients were included. Adherence studies lasting a year are 
already considered long term (81) and patients who are freshly prescribed 
treatment have poorer adherence (145). Persisting with treatment for 1 to 2.5 
years, but not implementing the treatment with a MPR ≥80%, can increase the 
pooled fracture risk up to 46% (81). This means there are still several patients at 
a higher risk of a fracture in Estonia despite being prescribed osteoporosis 
medicines, because they do not take them as prescribed. In the middle of the 
2000s, the number of patients taking more than 80% of prescribed medicines 
increased rapidly. This was probably due to once weekly medicines replacing 
once daily medicines that have lower adherence (146). 
 
 
6.5.3. Persistence 
Typically in adherence studies, 1-year persistence is used to identify persistent 
patients. However, persisting with treatment is not enough the patients also 
must take the medicines at the correct dosing intervals. It was established that in 
Estonia, 36.2% of patients persisted with osteoporosis treatment for at least one 
year and 19.8% for three years while maintaining a MPR ≥80% throughout the 
treatment course. 1-year persistence has been reported in earlier studies (147) 
over a range of 18%–75%. This wide difference in results is caused by the 
different methods used to assess persistence (e.g. data-derived, self-reported). 
Being persistent 3 years reduces fracture risk by 41% compared to being 
persistent for a month (143). Our results suggest that long-term persistence to 
osteoporosis medicines might be lower than observed before. 
 
 
6.5.4. Factors that influence secondary adherence 
Some patient characteristics predict poorer adherence (148) and several were 
found in the current study. Males were less adherent to treatment than females. 
This is not surprising as males tend to have poorer adherence across studies 
(149). However, as only 6% of osteoporosis patients were male, tackling them 
separately to improve their adherence to osteoporosis medicines would probably 
not result in a population wide health benefit. As males are expected to have 
poorer adherence than females in terms of taking medicines against other 
chronic diseases, a general intervention to improve the knowledge of males 
about the need to take medicines correctly is relevant. 
Patients’ age, an existent fracture, and the prescribing doctor seemed to 
significantly influence adherence. However, there is co-variance between these 
factors, because older people are at a greater risk of a fracture and patients with 
fractures are more often prescribed by specialist doctors, not their GPs. Taking 
this into account, it is hard to assess which of these factors has the largest 
impact on adherence, but as having a fracture has been shown to motivate 
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patients to take their medicines (150), this might be the key factor that makes 
patients adherent. 
Medicine affordability has also been shown to influence adherence (151). As 
the reimbursement rate of medicines increases from 75% to 90% at the age of 
63 in Estonia, this could explain – at least in part – the higher adherence to 
treatment in the age groups above 60 compared to the group 50–59. 
Substituting products was found not to have a negative outcome on 
adherence, as the number of different medicinal preparations available con-
taining the same active substance did not decrease adherence. This means that 
the cheapest alternative can be recommended to the patient in the pharmacy, as 
foreseen by legislation, without them worrying about using a generic sub-
stitution. The decisions taken by the state to increase the use of generic medici-
nes has raised some concerns amongst the general public, but our study estab-
lishes that adherence to osteoporosis medicines is not negatively affected by 
generic substitutions. 
 
 
6.5.5. Possible interventions 
Adherence to medicines is not easy to alter and the results of interventional 
studies are controversial, with for example phone call based interventions 
showing some effect in some studies (134,135,152) but having no effect on 
adherence in others (153–155). The importance of early identification of 
adherence problems has been stressed lately, with a proposal to base inter-
vention on bone turnover markers (156). If an ePrescriptions database could be 
used to identify poor adherence early on, it would definitely be less resource 
demanding and easier to implement than routine biomarker assessment. Prior 
research has come to the conclusion that when planning any intervention to 
improve adherence, it cannot address only one aspect of adherence or be 
oriented at one participant during the prescribing and dispensing process to be 
effective. It should be multidisciplinary and include patients, doctors, and 
pharmacists (84). It has also been shown that dispensing data, similar to what is 
available from the EHIF database, can be used to identify patients that are at 
risk of having poor adherence later on during the course of treatment based on 
their dispensing history (157).  
 
 
6.5.6. Expenditure 
Poor adherence to osteoporosis medicines leads to wasted money and the 
occurrence of avoidable fractures (158). Our study showed that 40% of the total 
expenditure on osteoporosis medicines was spent on treating patients who did 
not persist with treatment for at least a year. Spending on these medicines might 
not have served its purpose as the duration of treatment was suboptimal. If 3-
year persistence was used as the proxy for adherence, the percentage would 
53 
have been even higher. National health systems are working with constrained 
budgets and not adhering to treatment influences the cost-effectiveness of 
medicines. This means we do not spend the limited resources as efficiently as 
we hope, because the health benefits assumed from clinical trials are not 
achieved in every day practice. In addition to the lower cost-effectiveness, 
hospitalization costs and those of other medical services increase when patients 
do not adhere to treatment (159). These results highlight the importance of 
improving adherence, because inefficient use of resources and overspending 
postpones access to newer technologies. 
When the study period was divided into pre- and post-reimbursement 
periods it was seen that during the pre-reimbursement period the percent spent 
on ineffective treatment was substantially larger with 70.1% and decreased to 
32.5% in the post-reimbursement period. This change is in line with the in-
crease seen in the implementation of treatment. While in the middle of the 
2000s patients did not take their medicines very orderly but did much more so 
in the 2010s. This resulted in the decrease of money spent on ineffective treat-
ment. Still, approximately one third of the expenditure during the post-re-
imbursement period was for ineffective treatment. 
 
 
6.6. Limitations of the studies 
The main limitation of the utilization study was that the consumption data was 
based on wholesale data, which does not depict the actual amount of drugs that 
reached patients, but as pharmacies do not hold large stocks of medicines and 
order them from wholesalers as necessary, wholesale data correlates with 
pharmacy sales data rather well. ATC/DDD system was used to assess the 
potential number of patients. DDDs of osteoporosis medicines are very accurate 
as different dosing regimens are not used. Wholesale data also does not allow 
patient level analysis to assess prescribing quality or real treatment recommen-
dations for patients. 
The main limitation of the standardized hip fracture incidence study was 
using data from the EHIF database. The EHIF database is a claims database 
used by healthcare facilities to invoice the EHIF and different cases are not 
differentiated on the bills. This means the assumption was made that a patient 
breaks their hip only once a year, thus multiple fractures would go unnoticed. 
However, the number of patients with multiple fractures in one year is 
negligible. 
The main limitation of the primary adherence study was that the EHIF 
database does not include data on patients’ socio-demographic characteristics 
(for instance income) and thus the potential impact of these characteristics on 
primary adherence could not be assessed. In addition, due to technical reasons 
the use of other medicines by osteoporosis patients could not be analysed and 
the potential impact of polypharmacy on primary adherence. 
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The main limitation of the secondary adherence study was that dispensing 
data was used to assess adherence, but it is unknown whether the patient 
actually took the medicines they were dispensed. However, the use of MEMS in 
real life studies with tens of thousands of patients is impractical and prescribing 
databases have been shown to give a good estimate of the real use of medicines. 
Another limitation was that whether the prescribing of osteoporosis medicines 
was justified in every case could not be assessed and the reasons why patients 
stopped taking their medicines could not be analysed. 
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7. CONCLUSIONS 
I  The number of regular users of osteoporosis medicines is less than 10% 
of patients in risk of osteoporosis in Estonia, approximately 6,300 
patients. 
II  The level of consumption of osteoporosis medicines is rather similar in 
the Baltic countries, with the consumption trends also following similar 
patterns. 
III  The age standardized incidence of hip fractures started decreasing three 
years after higher reimbursement of osteoporosis medicines was 
established in 2007 and cheaper generic medicines came to market. The 
consumption of osteoporosis medicines doubled in two years from 2008 – 
2009. The decrease in fractures might in part be due to the increase in 
osteoporosis medicines consumption. 
IV  The trends of general consumption of osteoporosis medicines and the 
average daily dose price of these medicines moved in opposite directions. 
This suggests that consumption is affected at least in part by the price of 
medicines, especially when the medicines are expensive for patients. 
V  The PMN of osteoporosis medicines was found to be 13.1%, which is 
considerably lower than reported before. 42.0% of the initially PMN 
patients started treatment with a subsequent prescription. Half of these 
patients did so within 3 months of the initial prescription. 
VI  PMN was influenced by patients’ gender, age, diagnosis code, pre-
scribing doctor’s speciality, and prescribed active substance. 
VII  Eighty percent of patients purchased their initial osteoporosis medicine 
prescription within a week of the prescription and 95% did so within 25 
days. 
VIII 18.8% of patients were dispensed only one prescription. 44.2% of 
patients had a MPR ≥80% throughout the treatment course. 36.2% of 
patients persisted with treatment for one year with a MPR ≥80% and 
19.8% persisted for three years with good implementation. 
IX  Secondary adherence was influenced by patients’ age, gender, diagnosis 
code, prescribing doctor’s speciality, number of different active sub-
stances prescribed, and the number of different preparations dispensed. 
X  Forty percent of the expenditure on osteoporosis medicines was spent on 
patients who were non-adherent and did not persist for a year, thus the 
clinical effect hoped for might not have been achieved. 
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9. SUMMARY IN ESTONIAN 
Osteoporoosiravimite kasutamine, ravijärgimus ning 
osteoporoosist tingitud reieluu proksimaalse osa  
murdude trend Eestis 
Osteoporoos on krooniline haigus mida iseloomustab luukoe metabolismi tasa-
kaalu kaldumine luukoe lammutamise poole võrreldes luukoe moodustumisega 
(21). Sellest tulenevalt muutuvad inimese luud hapraks ning võivad kergesti 
murduda (9). Lähtuvalt üldisest elanikkonna vananemisest, inimeste elustiili 
muutusest ja linnastumisest eeldatakse, et osteoporoosist tingitud luumurdude 
hulk kasvab Euroopa Liidus 30% alates aastast 2010 aastaks 2025 ning sellega 
seotud kulutused suurenevad 121 miljardi euroni (17). 
Osteoporoosi raviks on olemas efektiivsed ravimid, mis tugevdavad pat-
sientide luukudet ning aitavad selle kaudu ära hoida luumurdude teket (49). 
Enamikes arenenud riikides on osteoporoosi valikravimiteks bisfosfonaadid 
ning järgmise reana kasutatakse denosumabi ning strontsium ranelaati. Osteo-
poroosi raviks on kasutusel ka selektiivsed östrogeeni retseptori modulaatorid 
ning paratüreoidhormoonid, kuid Eestis neid ei kasutata (54). Kõik osteoporoosi 
raviks kasutusel olevad ravimid on murdude vältimisel sarnase efektiivsusega 
ning kõigi nende efektiivsus on tõestatud kolm aastat kestnud kliinilistes 
uuringutes (47). Seega on efektiivseks osteoporoosiennetuseks vajalik kasutada 
ravimeid vähemalt kolm aastat. 
Peamine põhjus, miks ei saavuta patsiendid krooniliste haiguste ravil sar-
naseid tulemusi nagu on näidatud kliinilistes uuringutes, on ebapiisav ravi-
järgimus (6). Ravijärgimus iseloomustab seda kui hästi patsient järgib kokku-
lepitud raviskeemi (3). Ravijärgimuse võib jagada esmaseks ja teiseseks ravi-
järgimuseks (83). Esmane ravijärgimus kirjeldab kas patsient ostab välja talle 
väljastatud esimese retsepti ning teisene ravijärgimus kuidas patsient käitub 
peale seda kui ta on esmase retsepti välja ostnud (5). Teisest ravijärgimust võib 
omakorda jagada kolmeks etapiks: ravi alustamine, raviannuste võtmise 
korralikkus ning ravikestus (4). On oluline eristada millises ravijärgimuse etapis 
probleeme esineb, sest ebapiisava ravijärgimuse põhjused ning seega ka lahen-
dused on erinevates etappides erinevad. Piisavaks ravijärgimuseks loetakse kui 
patsient võtab vähemalt 80% talle ettenähtud raviannustest ning osteoporoo-
siravimite puhul jätkab raviga vähemalt kolme aasta vältel (141). 
Kui teisest ravijärgimust on mujal maailmas uuritud juba aastakümneid, siis 
esmase ravijärgimuse uuringuid on tehtud vähe, sest selleks ei ole piisavalt 
andmeid. Eesti Haigekassa retseptikeskus pakub hea võimaluse ka esmase 
ravijärgimuse uurimiseks, sest selles kajastub nii retsepti väljastamise info kui 
ka ravimi apteegist väljaostmise info. Euroopas on sarnane üleriigiline süsteem, 
mis hõlmab kõiki retseptide väljastajaid ning kõiki apteeke lisaks Eestile 
kasutusel veel ainult Taanis ning Rootsis (12). 
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Uurimistöö eesmärgid 
Uurimistööle seati järgnevad konkreetsed eesmärgid: 
1) Analüüsida osteoporoosiravimite summaarset kasutamist Eestis ning võrrel-
da seda teiste Balti riikidega; 
2) Analüüsida ravimite kasutamise ning osteoporoosist tingitud luumurdude 
esinemise omavahelist mõju; 
3) Välja selgitada esmase ja teisese ravijärgimuse määr Eestis ning neid mõju-
tavad patsiendi karakteristikud; 
4) Välja selgitada keskmine aeg, mis kulub osteoporoosiravimite retseptide 
välja kirjutamisest nende ostmiseni ning arvutada välja kulutused, mis tehti 
mitteefektiivsetele ravikuuridele. 
 
 
Patsiendid ja metoodika 
Ravimite kasutamise uuringutes (1. ja 2. uuring) kasutati andmeid Ravimiameti 
andmebaasist. Ravimiamet kogub ravimite hulgimüüjatelt 4 korda aastas aru-
andeid, mis peavad eristama kõiki müüdud pakendeid. Koondstatistika aval-
datakse Ravimiameti veebilehel ning eraldi Eesti kasutamist kirjeldava või Läti 
ja Leedu kolleegidega koostöös ühise Balti ravimite kasutamist kirjeldava 
raamatuna. 
Reieluu proksimaalse osa murdude trende kirjeldavas uuringus (2. uuring) 
kasutati lisaks Haigekassa tervishoiuteenuste andmebaasi ning Statistikaameti 
rahvastiku andmebaasi. Eelduseks võeti, et tõenäoliselt ei esine samal patsiendil 
korduvaid reieluu proksimaalseid murde sama aasta vältel ning arvestati iga 
patsiendi kohta ühte esmase murruga raviarvet aastas. 
Esmase ja teisese ravijärgimuse uuringutes (3. ja 4. uuring) kasutati Haige-
kassa retseptiandmebaasi. Esmase ravijärgimuse hindamiseks kasutati digi-
retsepti andmebaasi andmeid ning teisese ravijärgimuse hindamiseks ka varase-
mate paberretseptide alusel koostatud andmebaasi. Esmane ravijärgimus defi-
neeriti olukorrana kus patsient ostis oma esimese osteoporoosiravimi retsepti 
välja 60 päeva jooksul alates selle väljastamisest. Teisese ravijärgimuse uurin-
gus analüüsiti kõiki erinevaid ravijärgimuse etappe – ravi alustamist, ravi-
annuste võtmist ning ravikuuri kestust. Piisavaks ravijärgimuseks loeti olukord 
kui patsient võttis vähemalt 80% ettenähtud annustest ning jätkas ravi vähemalt 
ühe aasta vältel.  
 
 
Peamised tulemused 
Ravimite kasutamise uuring 
Osteoporoosi ravimite kasutamine suurenes 2000ndate aastate keskel ning teises 
pooles väga kiiresti. Aastatel 2004 kuni 2009 suurenes aastane keskmine kasu-
tamine 41%. Viimastel aastatel nende ravimite kasutamine Eestis enam oluliselt 
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ei muutunud. 2015.a oli osteoporoosiravimite kasutamine Eestis 4,8 DPD/1000/ 
ööpäevas, mis vastab umbes 6300 igapäevasele kasutajale. Samas hinnatakse 
osteoporoosi poolt ohustatuks Eestis ligikaudu 80 000 inimest (107), seega ei 
saa lugeda ravimi kasutamist Eestis piisavaks.  
 
 
Reieluu proksimaalse osa murdude trend 
Eestis esines aastatel 2004–2015 ligikaudu 1500 reieluu proksimaalse osa 
murdu aastas. Kui aastatel 2004–2010 oli trend pigem tõusev, aga statistiliselt 
mitteoluline, siis 2010 kuni 2015 vähenes standardiseeritud murrukordaja statis-
tiliselt oluliselt 4,5% aastas. Langustrend algas kolm aastat pärast seda kui 
osteoporoosiravimitele kinnitati kõrgem soodusmäär ning turule tulid genee-
rilised ravimid, mis langetas patsientide jaoks oluliselt nende ravimite hinda 
ning tõstis üldise kasutamise paari aastaga kahekordseks. Ravimite kasutamise 
trend ja ravimi keskmise päevadoosi hinna trend liikusid üksteisele vastupidises 
suunas (r = – 0,94; p<0,001). 
 
 
Esmase ravijärgimuse uuring 
Aastatel 2012–2015 väljastati esmakordselt osteoporoosiravi retsept 8404-le 
uuringukriteeriumitele vastanud patsiendile. 1100 (13,1%) ei ostnud oma esi-
mese retseptiga ravimit välja. Samas 462 patsienti (42,0% esmaselt ravijärgi-
matutest ning 5,5% kõikidest patsientidest) siiski alustas ravi mõne järgmise 
retseptiga. Pooled patsientidest alustasid ravi vähem kui kolm kuud pärast 
esmase retsepti väljastamist. Kolmele patsiendile väljastati uuringuperioodil 5 
osteoporoosiravimi retsepti, aga nad ei ostnud neist ühtki välja. 
Ligi pool patsientidest (45,7%) ostis oma esimese osteoporoosiravimi ret-
septi välja samal päeval kui see neile väljastati. Nädala jooksul ostis selle välja 
80,4% ning 25 päeva jooksul 95,0% patsientidest. Kui vaadelda kõiki osteopo-
roosiravimite retsepte, siis 66,3% nendest osteti välja enne kui olemasolev 
ravimivaru oli lõppenud või nädala jooksul peale uue retsepti väljastamist.  
Esmane ravijärgimus ei olnud meeste ja naiste puhul erinev. Luumurruga 
patisendid ostsid oma esimese retsepti tõenäolisemalt välja kui luumurruta pat-
siendid. Samuti osteti rohkem välja eriarstide kirjutatud retsepte kui perearstide 
omi. Toimeainetest osteti vähem välja esmaseid denosumabi ja strontsium 
ranelaadi retsepte võrreldes alendroonhappe omadega. Bisfosfonaatide vahel 
erinevusi ei olnud. Vanematel patsientidel oli parem esmane ravijärgimus kui 
noorematel. Tõenäosus ravijärgimuseks suurenes 7% iga lisanduva viie elu-
aastaga. 
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Teisese ravijärgimuse uuring 
Aastatel 2001–2015 alustas osteoporoosiravi Eestis 24 652 uuringukriteeriumi-
dele vastavat patsienti. Ainult ühe retseptiga ostis ravimit 18,8% patsientidest. 
Terve ravikuuri vältel ostis välja vähemalt 80% ettenähtud raviannustest 44,2% 
patsientidest. Vähemalt ühe aasta vältel ostis välja piisava hulga raviannustest 
36,2% patsientidest ja 19,8% patsientidest ostis ravimeid vähemalt kolm aastat 
piisava ravijärgimusega. 
Patsientidest, kes ostsid ravimit vähemalt kahe retseptiga, 47% pidasid 
ravimi võtmises lühemaid või pikemaid pause.  
Naistel oli 2,4 korda suurem tõenäosus läbida vähemalt aastane ravikuur hea 
ravijärgimusega. Võrreldes 50–59 aastaste patsientidega oli 60–69 aastastel 
20% parem ravijärgimus ning 70–79 aastastel 12% parem. Samas üle 80 aastas-
tel patsientidel ravijärgimus vähenes, võrreldes noorematega. Suurema kasuta-
tud ravimite või toimeainete arvu puhul oli patsientide ravijärgimus parem. 
Viieteistkümne aasta vältel kulutasid patsiendid omaosalusena ja Eesti 
Haigekassa kokku osteoporoosiravimite ostmiseks 14 172 142€. Sellest 40% 
kulus patsientide raviks kes ei võtnud ravimeid piisavalt korralikult või ei 
jätkanud ravi vähemalt aasta vältel. Jagades uuringuperioodi kaheks osaks: enne 
2007.a kui ravimitel ei olnud soodustust ning pärast 2007.a, siis esimesel 
perioodil maksid patsiendid 66,4% (1 939 517€) ja Haigekassa 33,6%  
(982 737€) ravimite hinnast ning teisel perioodil patsiendid 35,4% (3 984 510€) 
ja Haigekassa 64,6% (7 264 632€). Eeldatavalt ebaefektiivsele ravile (alla 80% 
annustest või lühem kui aastane ravikuur) kulus esimesel perioodil 70,1% rahast 
ning teisel perioodil 32,5%. 
 
 
Järeldused 
I  Igapäevaselt kasutab Eestis osteoporoosiravimeid vähem kui 10% osteo-
poroosiriskiga patsientidest, orienteeruvalt 6 300 inimest. 
II  Osteoporoosiravimite kasutamine Balti riikides on küllalt sarnane ning 
samuti on sarnased trendid, mida ravimite kasutamise muutus järgib ehk 
viimastel aastatel ei ole kasutamine üheski riigis oluliselt suurenenud. 
III  Vanusele standardiseeritud reieluu proksimaalse osa murdude arv hakkas 
Eestis vähenema kolm aastat pärast seda, kui osteoporoosiravimitele kinni-
tati aastal 2007 kõrgem soodustuse määr ning turule tulnud geneerilised 
ravimid suurendasid nende ravimite kasutamise aastatel 2008 kuni 2009 
kahekordseks. Murdude vähenemise põhjuseks võib osaliselt pidada ka 
ravimite kasutamise kasvu. 
IV  Osteoporoosiravimite üldine kasutamine ning keskmine ravimi päevadoosi 
maksumus muutusid uuringu vältel erisuunaliselt (r = -0,94). Ravimite 
kasutamine suurenes ning päevadoosi hind vähenes. Korrelatsioon oli 
tugevam 2000ndatel kui ravimid olid patsientide jaoks suhteliselt kallimad 
ning nõrgem 2010ndatel kui ravimite hind oli patsientide jaoks odavam, 
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aga kasutamise kasv siiski pidurdus. See näitab, et ravimite hinna langus 
võib positiivselt mõjutada ravimite kasutamise üldist taset, eelkõige juhul 
kui ravimite hind on patsientide jaoks suhteliselt kõrge. 
V  Oma esimese osteoporoosiravimi retsepti jätab Eestis välja ostmata 13,1% 
patsientidest, mis on oluliselt vähem kui leitud varasemates rahvusvahe-
listes uuringutes. Samuti leiti, et 42,0% patsientidest, kes jätsid oma esime-
se retsepti välja ostmata ostavad siiski ravimeid mõne järgmise retseptiga. 
Pooled nendest patsientidest ostsid ravimi välja vähem kui 3 kuud pärast 
esmase retsepti väljastamist. 
VI  Esmane ravijärgimus oli parem vanematel patsientidel (riskisuhe 1,07; 
p<0,001, iga lisanduva 5 eluaastaga), varasema luumurruga patsientidel 
(riskisuhe luumurruta patsientidel 0,78, p=0,001), patsientidel kellele mää-
ras ravimi ortopeed (riskisuhe 1,69 võrreldes perearstiga, p<0,001) või 
reumatoloog (riskisuhe 1,47 võrreldes perearstiga, p<0,001) ning kellele 
määrati bisfosfonaat (riskisuhe strontsium ranelaadil 0,67; p=0,037 ja 0,71 
denosumabil; p=0,05). 
VII  Kui patsient oma esimese retsepti välja ostab, siis teeb ta seda suhteliselt 
kiiresti pärast retsepti kirjutamist: kõigist ravimeid kasutanud patsientidest 
80,4% patsientidest ostsid oma esmase osteoporoosiravimi retsepti välja 
nädala jooksul peale retsepti kirjutamist ning 95,0% tegi seda 25 päeva 
jooksul.  
VIII Kõigist osteoporoosiravi alustanud patsientidest 18,8%-le väljastati ravimit 
ainult ühe retseptiga, 44,2% patsientidest ostsid kogu ravikuuri vältel 
apteegist välja 80% või rohkem ettenähtud ravimi annustest. Veidi rohkem 
kui kolmandik (36,2%) patsientidest võttis vähemalt 80% ettenähtud 
annustest vähemalt aasta jooksul ning 19,8% patsientidest vähemalt 3 aasta 
vältel. 
IX  Teisene ravijärgimus oli parem naistel (riskisuhe 2,37 võrreldes meestega, 
p<0,001), varasema luumurruga patsientidel (riskisuhe luumurruta patsien-
tidel 0,87; p<0,001), patsientidel kellele väljastas esimese retsepti ortopeed 
(riskisuhe 1,13 võrreldes perearstiga, p=0,018) või reumatoloog (riskisuhe 
1,47 võrreldes perearstiga, p<0,001) ning kes kasutasid ravikuuri jooksul 
rohkem erinevaid toimeaineid (riskisuhe 2,05 iga lisanduva toimeainega, 
p<0,001) või erinevaid ravimpreparaate (riskisuhe 1,91 iga lisanduva pre-
paraadiga, p<0,001). 
X  Aastatel 2001–2015 osteoporoosiravimitele kulunud rahast kulus 40% 
nende patsientide raviks, kellel ei olnud piisavalt hea ravijärgimus ning kes 
ei tarvitanud ravimeid vähemalt aasta vältel ja võib eeldada, et need pat-
siendid ei saanud ravimitest loodetavat kasu. 
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